Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided Adjuvant Therapy in Pancreatic Cancer
NCT06867146Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of fluorouracil, folinic acid, oxaliplatin, irinotecan, gemcitabine and 2 more in pancreatic cancer (PC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Disease-Free Survival at 18 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecangemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06867146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867146.